Premium
Measuring the cost‐effectiveness of hematopoietic growth factor therapy
Author(s) -
Finley Rebecca S.
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910515)67:10+<2727::aid-cncr2820671710>3.0.co;2-v
Subject(s) - medicine , rationing , psychological intervention , hematopoietic growth factor , intensive care medicine , cost effectiveness , identification (biology) , quality (philosophy) , health care , hematopoietic cell , risk analysis (engineering) , haematopoiesis , economics , nursing , philosophy , botany , stem cell , epistemology , biology , genetics , economic growth
The increasing cost of and demand for health care have intensified the concern that some form of health care rationing is inevitable. Cost studies require the identification, measurement, and comparison of all significant positive and negative consequences of alternative interventions and may evaluate benefit value, effectiveness, and effect on quality or quantity of life. The hematopoietic growth factors (HGF) will have far‐reaching effect on the practice of medicine and, therefore, the design of cost‐effectiveness studies are critically important in assessing economic effect.